Voriconazole for pulmonary aspergillosis: a case report underlining the necessity of drug monitoring

被引：0

作者：

van Gorp, F. ^{[1
]}

Vlek, A. L. M. ^{[2
]}

Pleizier, C. M. ^{[3
]}

Haas, L. E. M. ^{[4
]}

机构：

[1] Diakonessenhuis Utrecht, Dept Clin Pharm, Utrecht, Netherlands

[2] Diakonessenhuis Utrecht, Dept Med Microbiol & Immunol, Utrecht, Netherlands

[3] Diakonessenhuis Utrecht, Dept Neurol, Utrecht, Netherlands

[4] Diakonessenhuis Utrecht, Dept Intens Care, Utrecht, Netherlands

来源：

NETHERLANDS JOURNAL OF CRITICAL CARE | 2022年 / 30卷 / 03期

关键词：

voriconazole; therapeutic drug monitoring; invasive pulmonary aspergillosis; pharmacogenomics; SERUM CONCENTRATION; EFFICACY; SAFETY;

D O I：

暂无

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

Voriconazole is commonly used for the treatment of invasive pulmonary aspergillosis. Recent guidelines strongly advise routine therapeutic drug monitoring for patients receiving voriconazole. We present a case with subtherapeutic voriconazole serum levels caused by drug interactions and genetic polymorphisms.

引用

页码：111 / 113

页数：3

共 10 条

[1] Phenytoin-induced reduction of voriconazole serum concentration is not compensated by doubling the dosage
Alffenaar, Jan-Willem C.
van der Elst, Kim C. M.
Uges, Donald R. A.
Kosterink, Jos G. W.
Daenen, Simon M. G. J.
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (03) : 462 - 463
[2] Autmizguine J, 2012, PHARMACOGENOMICS, V13, P1961, DOI [10.2217/PGS.12.175, 10.2217/pgs.12.175]
[3] Dutch Working Party on Antibiotic Policy, 2017, SWAB GUIDELINES MANA
[4] Ebrahimpour S, 2017, J RES PHARM PRACT, V6, P151, DOI 10.4103/jrpp.JRPP_17_31
[5] Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
Herbrecht, R
Denning, DW
Patterson, TF
Bennett, JE
Greene, RE
Oestmann, JW
Kern, WV
Marr, KA
Ribaud, P
Lortholary, O
Sylvester, R
Rubin, RH
Wingard, JR
Stark, P
Durand, C
Caillot, D
Thiel, E
Chandrasekar, PH
Hodges, MR
Schlamm, HT
Troke, PF
de Pauw, B
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) : 408 - 415
[6] Jenks Jeffrey D, 2015, Infect Dis Clin Pract (Baltim Md), V23, P227
[7] The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial
Park, Wan Beom
Kim, Nak-Hyun
Kim, Kye-Hyung
Lee, Seung Hwan
Nam, Won-Seok
Yoon, Seo Hyun
Song, Kyoung-Ho
Choe, Pyoeng Gyun
Kim, Nam Joong
Jang, In-Jin
Oh, Myoung-don
Yu, Kyung-Sang
[J]. CLINICAL INFECTIOUS DISEASES, 2012, 55 (08) : 1080 - 1087
[8] Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
Pascual, Andres
Calandra, Thierry
Bolay, Saskia
Buclin, Thierry
Bille, Jacques
Marchetti, Oscar
[J]. CLINICAL INFECTIOUS DISEASES, 2008, 46 (02) : 201 - 211
[9] Pharmacokinetic/pharmacodynamic profile of voriconazole
Theuretzbacher, Ursula
Ihle, Franziska
Derendorf, Hartmut
[J]. CLINICAL PHARMACOKINETICS, 2006, 45 (07) : 649 - 663
[10] Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
Ullmann, A. J.
Aguado, J. M.
Arikan-Akdagli, S.
Denning, D. W.
Groll, A. H.
Lagrou, K.
Lass-Floerl, C.
Lewis, R. E.
Munoz, P.
Verweij, P. E.
Warris, A.
Ader, F.
Akova, M.
Arendrup, M. C.
Barnes, R. A.
Beigelman-Aubry, C.
Blot, S.
Bouza, E.
Bruggemann, R. J. M.
Buchheidt, D.
Cadranel, J.
Castagnola, E.
Chakrabarti, A.
Cuenca-Estrella, M.
Dimopoulos, G.
Fortun, J.
Gangneux, J. -P.
Garbino, J.
Heinz, W. J.
Herbrecht, R.
Heussel, C. P.
Kibbler, C. C.
Klimko, N.
Kullberg, B. J.
Lange, C.
Lehrnbecher, T.
Loeffler, J.
Lortholary, O.
Maertens, J.
Marchetti, O.
Meis, J. F.
Pagano, L.
Ribaud, P.
Richardson, M.
Roilides, E.
Ruhnke, M.
Sanguinetti, M.
Sheppard, D. C.
Sinko, J.
Skiada, A.
[J]. CLINICAL MICROBIOLOGY AND INFECTION, 2018, 24 : E1 - E38

← 1 →